Thomas B. Casale, MD

Thomas Casale, MD, discusses pooled CUPID A and C data showing dupilumab improved quality of life in omalizumab-naive chronic spontaneous urticaria.

Real-world data show epinephrine nasal spray achieved an 89.2% success rate in treating anaphylaxis, nearly identical to the injection’s response rate.

One year after neffy's approval, 4 clinicians and 1 PharmD examine its continuing impact on the field.

Casale discussed data from the phase 3 LIBERTY-CSU CUPID studies evaluating dupilumab’s use in urticaria.

Casale discussed data from the phase 1b/2a BEACON study he presented at the AAAAI/WAO Joint Congress.